Skip to Content
MilliporeSigma
All Photos(1)

Documents

B0200000

Baclofen

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Baclofen, (±)-β-(Aminomethyl)-4-chlorobenzenepropanoic acid, Lioresal

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H12ClNO2
CAS Number:
1134-47-0
Molecular Weight:
213.66
MDL number:
MFCD00055143
UNSPSC Code:
41116107
PubChem Substance ID:
329773100
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

baclofen

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

ClC1=CC=C(C(CN)CC(O)=O)C=C1

InChI

1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)

InChI key

KPYSYYIEGFHWSV-UHFFFAOYSA-N

Gene Information

human ... GABBR1(2550) , GABBR2(9568)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Baclofen EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

GABAB receptor agonist; skeletal muscle relaxant; antispastic agent.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tamis W Pin et al.
Developmental medicine and child neurology, 53(10), 885-895 (2011-06-04)
Studies on the use of intrathecal baclofen (ITB) for ambulant adults with spasticity and/or dystonia of cerebral origin are scarce, and are even more limited for children and adolescents. This systematic review investigates the use of ITB to improve walking
Giovanni Addolorato et al.
Current pharmaceutical design, 16(19), 2113-2117 (2010-05-21)
Preclinical studies show that antagonism of the GABA(B) receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABA(B) receptor antagonist baclofen may represent
Susan Sangha et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(10), 2405-2413 (2014-04-15)
Accurate discrimination of environmental cues predicting reward, fear, or safety is important for survival. The prelimbic and infralimbic cortices are implicated in regulating reward-seeking and fear behaviors; however, no studies have examined their roles in discriminating among reward, fear, and
Roberta Agabio et al.
European addiction research, 19(6), 325-345 (2013-06-19)
It has been reported that baclofen, a drug used in the treatment of spasticity, reduces the severity of withdrawal symptoms and substance use disorders (SUDs) for some psychoactive drugs. To evaluate the effectiveness and safety of baclofen in the treatment
Amanda McIntyre et al.
The journal of spinal cord medicine, 37(1), 11-18 (2013-10-05)
To review the available evidence on the effectiveness of intrathecal baclofen in the treatment of spasticity in individuals with spinal cord injuries (SCIs) at least 6 months post-injury or diagnosis. A literature search of multiple databases (Pub Med, CINAHL, EMBASE)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service